^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

KIT (KIT proto-oncogene, receptor tyrosine kinase)

i
Other names: KIT, KIT proto-oncogene receptor tyrosine kinase, C-Kit, CD117, PBT, SCFR, Stem Cell Factor Receptor, V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
2d
Sinonasal mucosal melanoma: REFCOR guidelines for diagnosis, treatment and follow-up. (PubMed, Eur Ann Otorhinolaryngol Head Neck Dis)
Strong agreement: it is recommended to perform systematic regional and remote extension assessment at diagnosis; PET-CT is the gold standard for remote assessment; isolated radiotherapy is not recommended for curative treatment; given the major risk of metastasis and the poor prognosis, alternatives to heavy destructive surgery should be considered in the rare cancer multidisciplinary tumor board; it is recommended to screen for NRAS, BRAF and KIT mutations, to identify possible treatment targets; reference imaging should be performed 3 months after end of treatment, using sinonasal and brain MRI and PET-CT; due to the risk of early recurrence, close follow-up is recommended during the first 2 years, then at least every 6 months up to 5 years postoperatively. Relative agreement: operable sinonasal mucosal melanoma should be treated by total macroscopic resection with negative margins followed by radiotherapy on the tumor bed; postoperative radiotherapy is recommended, to improve local control; neoadjuvant or adjuvant chemotherapy, other than immunotherapy or targeted therapy, is not recommended; for non-resectable and/or metastatic sinonasal mucosal melanoma, immunotherapy is the systematic first-line treatment; prophylactic lymph-node treatment is not recommended in N0 sinonasal mucosal melanoma; lymph-node surgery is recommended in N+ cases without remote metastasis, including cases of regional recurrence.
Clinical guideline • Journal • IO biomarker
|
BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
|
BRAF mutation • KIT mutation
3d
Myeloid neoplasms with mutated KIT: comparative clinicopathologic analysis of D816 vs. non-D816 variants. (PubMed, Cancer Genet)
Our findings suggest that non-D816 KIT mutations are associated with a less aggressive clinical phenotype, lower mast-cell differentiation, and improved outcomes. These results support a biologically distinct role of non-D816 KIT variants in MNs and highlight the need for refined risk stratification incorporating KIT variant classes.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)
|
KIT mutation
4d
Stem cell activation in organ culture reveals novel transcriptional programs underlying metabolic, fibrotic, vascular, and immune dysregulation in uterine leiomyomas. (PubMed, Front Cell Dev Biol)
Long-term organ culture recapitulates key molecular features of fibroids and reveals tissue-specific mechanisms governing stem cell activation and differentiation. These findings identify potential therapeutic opportunities and establish long-term organ culture as a robust, physiologically relevant platform for investigating normal and tumor biology.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto) • CD24 (CD24 Molecule) • HMGA2 (High mobility group AT-hook 2) • PLAG1 (PLAG1 Zinc Finger) • PLIN2 (Perilipin) • ITGA2 (Integrin Subunit Alpha 2) • KLF10 (Kruppel Like Factor 10) • MED12 (Mediator Complex Subunit 12)
|
KIT expression
4d
CAR T-cells targeting CD117 effectively eliminate mast cells in preclinical models of advanced systemic mastocytosis. (PubMed, Leukemia)
Furthermore, in immunocompromised mice engrafted with an advSM-like MC cell line, repetitive applications of anti-CD117-CAR T-cells were able to inhibit MC expansion. These data may pave the way for the development of anti-CD117-CAR T-cell therapies in advSM.
Preclinical • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase)
7d
The contribution of stem cell factor and its receptor c-Kit to cancer-induced bone pain. (PubMed, JCI Insight)
When FGF1 was knocked down in DRGs, SCF-mediated nerve sprouting was prevented. Taken together, our studies demonstrate the importance of the SCF/c-Kit axis in CIBP and nerve sprouting, and identify the SCF/c-Kit/FGF1 pathway as a potential therapeutic target for CIBP.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase)
7d
StrateGIST 1: First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (clinicaltrials.gov)
P1, N=278, Recruiting, IDRX, Inc., a wholly owned subsidiary of GSK, LLC | Trial completion date: Nov 2027 --> Jun 2028 | Trial primary completion date: Nov 2027 --> Mar 2027
Trial completion date • Trial primary completion date • First-in-human
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
|
KIT mutation • PDGFRA mutation • PDGFRA exon 18 mutation
|
sunitinib • velzatinib (GSK6042981)
8d
Rare Case of Appendiceal Gastrointestinal Stromal Tumor: Diagnosis, Surgical Management, and Long-term Outcome. (PubMed, Cancer Diagn Progn)
Owing to their rarity and small size, appendiceal GISTs are often discovered incidentally and may present diagnostic challenges. Herein, we report a rare case of appendiceal GIST detected preoperatively and successfully treated by laparoscopic appendectomy, with long-term recurrence-free survival.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD34 (CD34 molecule)
8d
Small bowel volvulus revealing advanced jejunal gastrointestinal stromal tumor with diffuse metastases: a case report. (PubMed, Ann Med Surg (Lond))
The patient recovered uneventfully and was started on treatment with imatinib mesylate...GISTs should be considered in cases of unexplained SBV. This case emphasizes the diagnostic challenges, the need for prompt surgical palliation, and the role of systemic tyrosine kinase inhibitors in advanced presentation of GIST.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • ANO1 (Anoctamin 1)
|
imatinib
8d
Targeting the Unmet Need in Gastrointestinal Stromal Tumors: A Contemporary Review of Investigational Clinical Trials and Therapeutic Landscape. (PubMed, Pharmaceuticals (Basel))
Although tyrosine kinase inhibitors (TKIs), particularly imatinib, have substantially improved outcomes, most patients with advanced disease eventually develop resistance, resulting in disease progression...Molecular stratification and personalized approaches dominate ongoing research, but evidence generation remains limited by small sample sizes and slow recruitment. Future trials integrating innovative therapeutic platforms and patient-centered outcomes are essential to improve long-term disease control and quality of life.
Review • Journal • IO biomarker
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
|
KIT mutation • PDGFRA mutation
|
imatinib
8d
Circulating Plasma Cells as a Minimally Invasive Adjunct to Bone Marrow Aspirates for Genetic Analysis of ER Stress and Autophagy in Multiple Myeloma: A Feasibility Study. (PubMed, Biomedicines)
A secondary objective was to assess whether mRNA expression levels of the endoplasmic reticulum (ER) stress sensors X-box-binding protein 1 (uXBP1) and activating transcription factor 6 (ATF6), and the chaperone-mediated autophagy marker Lysosomal-Associated Membrane Protein 2 (LAMP2A) by droplet digital PCR (ddPCR), were associated with resistance to the second-generation proteasome inhibitor (PI) carfilzomib (Cfz)...Samples were obtained as part of standard clinical care and/or during treatment with Bortezomib (Btz) or Cfz...Cfz adaptation was associated with reduced levels of uXBP1 and LAMP2A mRNA in MM cell lines. Future prospective studies evaluating the clinical utility of ER stress and chaperone-mediated autophagy associated transcripts in CPCs as predictors of resistance to PI are warranted.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • SDC1 (Syndecan 1) • ATF6 (Activating Transcription Factor 6) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • XBP1 (X-box-binding protein 1) • LAMP2 (Lysosomal Associated Membrane Protein 2)
|
bortezomib • carfilzomib
8d
Genomic profiling and therapeutic targets of Thai melanoma revealed by next-generation sequencing. (PubMed, Sci Rep)
Notably, patients harboring KIT mutations showed a trend toward shorter disease-free survival, suggesting a potential prognostic role that warrants further investigation. These findings provide initial genomic understanding of Thai melanoma and highlight candidate actionable mutations for future precision oncology research.
Journal • Next-generation sequencing
|
BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
|
BRAF V600E • BRAF V600 • KIT mutation • RAS mutation
|
Oncomine™ Comprehensive Assay Plus
10d
NTRK Fusion Landscape in 195 Positive Cases of 17 Tumors: A Chinese Multicenter Retrospective Study with Optimized Pan-TRK IHC Screening. (PubMed, Mod Pathol)
Particularly, the detection sensitivity for NTRK3 fusions was significantly enhanced and reached 95.89 %. This study contributes to clarifying NTRK fusion distribution in patients and validates a standardized, sensitive pan-TRK IHC strategy for clinical screening.
Retrospective data • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • NTRK (Neurotrophic receptor tyrosine kinase) • TFAM (Transcription Factor A, Mitochondrial)
|
NTRK positive • NTRK fusion
|
VENTANA pan-TRK (EPR17341) Assay